Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 6/20 | 0.61 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.55 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | MLYCD | O95822 | 1/20 | 0.55 |
| ▸ | ERN1 | O75460 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14361896 | 0.88 | PHGDH (0.67) | PHGDHHPGDAKR1C3TSHRALDH1A1 | |
| SCHEMBL14358433 | 0.88 | PHGDH (0.67) | PHGDHHPGDAKR1C3TSHRALDH1A1 | |
| SCHEMBL10720943 | 0.87 | PHGDH (0.81) | PHGDHHPGDAKR1C3TSHRALDH1A1 | |
| SCHEMBL4906405 | 0.85 | PHGDH (0.63) | PHGDHHPGDAKR1C3TSHRALDH1A1 | |
| SCHEMBL31428753 | 0.85 | PKM (0.55) | PHGDHHPGDTSHRALDH1A1L3MBTL1 | |
| SCHEMBL6223960 | 0.84 | HPGD (0.70) | HPGDTSHRALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL6617073 | 0.82 | HPGD (0.74) | HPGDTSHRALDH1A1L3MBTL1MAPK1 | |
| SCHEMBL22708679 | 0.82 | PHGDH (0.59) | PHGDHHPGDAKR1C3TSHRALDH1A1 | |
| SCHEMBL28296651 | 0.82 | HPGD (0.86) | PHGDHHPGDAKR1C3TSHRALDH1A1 | |
| SCHEMBL2666919 | 0.81 | ERN1 (0.61) | HPGDTSHRALDH1A1L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-24 | — | — | US | disclosed |
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
| CN-119350433-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2025-01-24 | — | — | CN | disclosed |
| US-12195427-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2025-01-14 | — | — | US | disclosed |
| CN-112867706-B | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118373875-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-07-23 | — | — | CN | disclosed |
| CN-117964684-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117964683-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| US-6265381-B1 | MORPHOLINOUREA AND RELATED DERIVATIVES OF PENTAFLUOROETHYL PEPTIDES | MERRELL PHARMACEUTICALS, INC. | 2001-07-24 | — | — | US | disclosed |
| US-6008196-A | AN ENZYME INHIBITORS OF HUMAN NEUTROPHIL ELASTASE | HOECHST MARION ROUSSEL, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| EP-0763055-B1 | PERFLUOROALKYL KETONE INHIBITORS OF ELASTASE AND PROCESSES FOR MAKING THE SAME | MERRELL PHARMA INC (US) | 1999-11-03 | — | — | EP | disclosed |
| US-5714470-A | PENTAFLUORO ALKYL TERMINATED PEPTIDE DERIVATIVES; TREATMENT OF INFLAMMATORY DISEASES, EMPHYSEMA AND CHRONIC BRONCHITIS | MERRELL PHARMACEUTICALS, INC. (US) | 1998-02-03 | — | — | US | disclosed |
| EP-0763055-A1 | PERFLUOROALKYL KETONE INHIBITORS OF ELASTASE AND PROCESSES FOR MAKING THE SAME | MERRELL PHARMACEUTICALS INC. (US) | 1997-03-19 | — | — | EP | disclosed |
| EP-0529568-B1 | Novel orally-active elastase inhibitors | MERRELL PHARMA INC (US) | 1997-01-15 | — | — | EP | disclosed |
| US-5478811-A | Antiinflammatory agents, enzyme inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1995-12-26 | — | — | US | disclosed |
| WO-1995033762-A1 | PERFLUOROALKYL KETONE INHIBITORS OF ELASTASE AND PROCESSES FOR MAKING THE SAME | MERRELL PHARMACEUTICALS INC. (US) | 1995-12-14 | — | — | WO | disclosed |
| EP-0529568-A1 | Novel orally-active elastase inhibitors | MERRELL PHARMACEUTICALS INC. (US) | 1993-03-03 | — | — | EP | disclosed |
| US-4289769-A | HYPOTENSIVE | AMERICAN CYANAMID COMPANY (US) | 1981-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | PHGDH 4068/4885HPGD 4233/4885AKR1C3 941/4885 |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | PHGDH 4043/4885HPGD 4052/4885AKR1C3 4577/4885 |
| US-12195427-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | PHGDH 4043/4885HPGD 4052/4885AKR1C3 4577/4885 |
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | PHGDH 4109/4885HPGD 3962/4885AKR1C3 4587/4885 |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | PHGDH 4043/4885HPGD 4052/4885AKR1C3 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.